| HOME >> MEDICINE >> TECHNOLOGY |
31.9 %34.1 %33.5 %35.9 %Operating expenses
28.3 %28.3 %28.6 %28.6 %Operating income
3.6 %5.8 %4.9 %7.2 %Six Months EndedOtherDecember 29, 2012December 31, 2011% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales
$
34,948$
-$
34,948$
37,280$
-$
37,280-6 %-6 %Cost of sales
23,546800
(a)
22,74625,393875
(a)
24,518-7 %-7 %Gross profit
11,40280012,20211,88787512,762-4 %-4 %Operating expenses
10,314-10,31410,678-10,678-3 %-3 %Operating income
$
,088$
800$
,888$
,209$
875$
2,084-10 %-9 %Selected ratios as a percentage of net salesGross profit
32.6 %34.9 %31.9 %34.2 %Operating expenses
29.5 %29.5 %28.6 %28.6 %Operating income
3.1 %5.4 %3.2 %5.6 %(a) Deal-related amortization(b) Inventory step-up of $7,693(c) Severance costs(d) Inventory step-up of $27,179(e) Proceeds of $3,500 from sale of pipeline development projects(f) Severance costs of $3,755 Table IIIPERRIGO COMPANYFY 2013 GUIDANCE AND FY 2012 EPSRECONCILIATION OF NON-GAAP MEASURES(unaudited)Full YearFiscal 2013 GuidanceFY13 reported diluted EPS range (2)$4.73 - $4.93Deal-related amortization (1,2)0.63Charge associated with inventory step-up (2)0.05Charges associated with acquisition and severance costs(2)0.02Loss on sale of investment0.02FY13 adjusted diluted EPS range$5.45 - $5.65Fiscal 2012*FY12 reported diluted EPS from continuing operations$4.18Deal-related amortization (1)0.523Charge associated with inventory step-up0.181Charges associated with acquisition-related and severance costs0.062Charges associated with restructuring0.061Net charge associated with acquired R&D and proceeds from sale of IPR&D projects0.012Earnings
'/>"/>
| SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved |